Latest From Scynexis Inc.
Biotech plans to file its first-in-class triterpenoid agent for approval in 2020 following a second Phase III study in acute vulvovaginal candidiasis. Beyond that, it hopes for a supplemental approval in recurrent VVC.
Scynexis highlights enrollment exceeding expectations in Phase III VVC trials; Daré prepares to enter Phase III to treat BV.
Scrip looks at some the key clinical and regulatory pharma events that will spark attention during the next three months, according to Biomedtracker's latest quarterly outlook report.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Therapeutic Areas
- Infectious & Viral Diseases
- ScyRex Inc.
- Scynexis Chemistry & Automation Inc.
- North America
- Parent & Subsidiaries
- Scynexis Inc.
- Senior Management
Marco Taglietti, MD, Pres. & CEO
Eric Francois, CFO
David Angulo, MD, CMO
- Contact Info
Phone: (201) 884-5485
1 Evertrust Plaza, 13th Fl.
Jersey City, NJ 07302
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.